MS
VRDN icon

Maven Securities’s Viridian Therapeutics VRDN Stock Holding History

Maven Securities’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,000
Closed -$467K – 553
2025
Q4 		$467K Buy
+15,000
New +$411K 0.01% 432
2022
Q2 		– Sell
-27,486
Closed -$508K – 1134
2022
Q1 		$508K Buy
27,486
+5,535
+25% +$106K 0.02% 537
2021
Q4 		$434K Sell
21,951
-118,049
-84% -$2.2M 0.01% 596
2021
Q3 		$2.3M Buy
+140,000
New +$2.05M 0.07% 205
2021
Q2 		– Sell
-27,898
Closed -$470K – 1355
2021
Q1 		$470K Buy
+27,898
New +$522K 0.02% 694

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Maven Securities's VRDN Position: Q1 2026 in Review

Maven Securities sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 15,000 shares — an estimated $467K sold.

Maven Securities first reported a position in VRDN in Q1 2021 and held it in 5 quarters. The position peaked at $2.3M in Q3 2021. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Maven Securities reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Maven Securities sold 15,000 Viridian Therapeutics shares in Q1 2026, an estimated $467K.
  • Maven Securities first reported a position in Viridian Therapeutics in Q1 2021 and held it in 5 quarters.
  • Maven Securities's Viridian Therapeutics position peaked at $2.3M in Q3 2021.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.